Search

Your search keyword '"Lánská, Miriam"' showing total 34 results
Start Over Author "Lánská, Miriam"
34 results on '"Lánská, Miriam"'

1. The world apheresis association registry, 2023 update

Author

Vrielink, Hans, Le Poole, Kaatje, Stegmayr, Bernd, Kielstein, Jan, Berlin, Gösta, Ilhan, Osman, Seval, Guldane Cengiz, Prophet, Heinrich, Aandahl, Astrid, Deeren, Dries, Bojanic, Ines, Blaha, Milan, Lanska, Miriam, Gasova, Zdenka, Bhuiyan-Ludvikova, Zdenka, Blahutova, Sarka, Hrdlickova, Radomira, Audzijoniene, Judita, Griskevicius, Antanas, Glatt, Tanya, Strineholm, Virginia, Ott, Michael, Nilsson, Thomas, Newman, Elizabeth, Derfler, Kurt, Witt, Volker, and Toss, Fredrik

Published
2023
Full Text
View/download PDF

2. Preservation and Storage of Cells for Therapy: Current Applications and Protocols

Author

Acker, Jason P., primary, Bondarovych, Mykola, additional, Brunotte, Ricarda, additional, Buriak, Iryna A., additional, Fuller, Barry J., additional, Glasmacher, Birgit, additional, Goltsev, Anatoliy M., additional, Gregor, Jiří, additional, Gryshkov, Oleksandr, additional, Herrity, Kieran, additional, Honegrová, Barbora, additional, Hunt, Charles J., additional, Jandová, Miroslava, additional, Johnstone, Brian H., additional, Kilbride, Peter, additional, Lánská, Miriam, additional, Mann, Jennifer, additional, Měřička, Pavel, additional, Musall, Kelsey G., additional, Mutsenko, Vitalii, additional, Mykhailova, Olga, additional, Petrenko, Yuriy, additional, Radocha, Jakub, additional, Sherry, Aubrey M., additional, Stacey, Glyn Nigel, additional, Štěrba, Lubomír, additional, Vokurková, Doris, additional, William, Nishaka, additional, and Woods, Erik J., additional

Published
2022
Full Text
View/download PDF

4. Perspective: The Role of Cryopreservation Techniques in Manufacturing, Transport, and Storage of Car-T Therapy Products

Author

Jandová, Miroslava, primary, Stacey, Glyn Nigel, additional, Lánská, Miriam, additional, Gregor, Jií, additional, Rozsívalová, Petra, additional, Beková, Lenka, additional, Woidigová Ducháová, Zuzana, additional, Belada, David, additional, Radocha, Jakub, additional, Měřička, Pavel, additional, and Fuller, Barry, additional

Published
2023
Full Text
View/download PDF

8. Hypolipidemická terapie u těhotných žen s homozygotní familiární hypercholesterolemií.

Author

Veletová, Kateřina, Blaha, Vladimír, Bláha, Milan, Lánská, Miriam, and Žák, Pavel

Subjects
FAMILIAL hypercholesterolemia, LIPID metabolism disorders, HOMOZYGOUS familial hypercholesterolemia, PREGNANCY complications, ABORTION, DYSLIPIDEMIA
Abstract

Copyright of Remedia is the property of Medical Tribune CZ, s.r.o. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2022

9. Therapeutic Apheresis, Circulating PLD, and Mucocutaneous Toxicity: Our Clinical Experience through Four Years

Author

Filip, Stanislav, Kubeček, Ondřej, Špaček, Jiří, Lánská, Miriam, Bláha, Milan, and Martínková, Jiřina

Subjects
lcsh:Pharmacy and materia medica, enzymes and coenzymes (carbohydrates), pegylated liposomal doxorubicin, therapeutic apheresis, chemotoxicity, lcsh:RS1-441, lipids (amino acids, peptides, and proteins), Review, palmar-plantar erythrodysesthesia, chemotherapy
Abstract

Cancer treatment has been greatly improved by the combined use of targeted therapies and novel biotechnological methods. Regarding the former, pegylated liposomal doxorubicin (PLD) has a preferential accumulation within cancer tumors, thus having lower toxicity on healthy cells. PLD has been implemented in the targeted treatment of sarcoma, ovarian, breast, and lung cancer. In comparison with conventional doxorubicin, PLD has lower cardiotoxicity and hematotoxicity; however, PLD can induce mucositis and palmo-plantar erythrodysesthesia (PPE, hand-foot syndrome), which limits its use. Therapeutical apheresis is a clinically proven solution against early PLD toxicity without hindering the efficacy of the treatment. The present review summarizes the pharmacokinetics and pharmacodynamics of PLD and the beneficial effects of extracorporeal apheresis on the incidence of PPE during chemoradiotherapy in cancer patients.

Published
2020

10. Complex karyotype in a younger patient with chronic lymphocytic leukemia

Author

Šimkovič, Martin, primary, Smolej, Lukáš, additional, Kašparová, Petra, additional, Rabasová, Jana, additional, Havlíková, Pavlína, additional, Écsiová, Dominika, additional, Vodárek, Pavel, additional, Lánská, Miriam, additional, Radocha, Jakub, additional, Belada, David, additional, and Žák, Pavel, additional

Published
2021
Full Text
View/download PDF

27. The importance of rheological parameters in the therapy of the dry form of age-related macular degeneration with rheohaemapheresis

Author

Bláha, Milan, primary, Rencová, Eva, additional, Langrová, Hana, additional, Lánská, Miriam, additional, Bláha, Vladimír, additional, Studnička, Jan, additional, Rozsíval, Pavel, additional, Malý, Radovan, additional, Fátorová, Ilona, additional, Filip, Stanislav, additional, Dršata, Jakub, additional, Hejsek, Libor, additional, and Malý, Jaroslav, additional

Published
2012
Full Text
View/download PDF

33. [Position of lipoprotein apheresis in present].

Author

Bláha V, Bláha M, Lánská M, Havel E, Vyroubal P, Zadák Z, Vrablík M, Piťha J, Žák P, and Sobotka L

Subjects
Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Hyperlipoproteinemia Type II blood, Hypolipidemic Agents therapeutic use, Blood Component Removal methods, Hyperlipoproteinemia Type II therapy, Lipoproteins blood
Abstract

Lipoprotein apheresis (LA) is an effective treatment method the patients with severe hypercholesterolemia, resistant to the standard therapy. LA is an extracorporeal elimination technique, which specifically removes low density lipoprotein (LDL) cholesterol from the circulation. At present, lipoprotein apheresis, combined with high-dose statin and ezetimibe therapy, is the best available means of treating patients with homozygous and statin refractory heterozygous familial hypercholesterolaemia (FH). However, the extent of cholesterol-lowering achieved is often insufficient to meet the targets set by current guidelines. The recent advent of new classes of lipid-lowering agents provides new hope that the latter objective may now be achievable. These compounds act either by reducing low density lipoprotein (LDL) cholesterol production by inhibiting apolipoprotein B synthesis with an antisense oligonucleotide (mipomersen), or by inhibiting microsomal triglyceride transfer protein (lomitapid), or by enhancing LDL catabolism via monoclonal antibody-mediated inhibition of the activity of proprotein convertase subtilisin/kexin 9 (PCSK9-alirocumab, evolocumab etc). The promising is the combination of LDL-apheresis with new drugs, namely for its potential to further decrease of LDL-cholesterol between apheresis. Depending on the outcome of current trials, it seems likely that these compounds, used alone or combined with lipoprotein apheresis, will markedly improve the management of refractory FH.

Published
2015

34. [LDL-apheresis in the treatment familial hypercholesterolemia].

Author

Bláha V, Bláha M, Lánská M, Havel E, Vyroubal P, Zadák Z, Žák P, and Sobotka L

Subjects
Cholesterol, HDL blood, Cholesterol, LDL blood, Humans, Triglycerides blood, Blood Component Removal methods, Hyperlipoproteinemia Type II blood, Hyperlipoproteinemia Type II therapy
Abstract

LDL-apheresis is an extracorporeal elimination technique, which specifically removes LDL-cholesterol from the circulation. There are six methods for the selective LDL-cholesterol removal these days. The main indications for LDL-apheresis are the diagnosis of homozygous familial hypercholesterolemia, heterozygous familial hypercholesterolemia which is refractory the standard care and intolerance of routine care, and also patients with lipoprotein(a) increase resistant to the farmacotherapy. There is still debate which LDL-cholesterolemia is indication for LDL-apheresis therapy, and the recommendation differs among various countries. Despite large randomized trials are missing, there are several good quality studies to conclude, that the beneficial cardiovascular effects of LDL-apheresis in severe hypercholesterolemia are important and beneficial.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results